RDiscovery is a therapeutic-focused incubator that transforms early-stage life sciences into therapeutics. We are committed to sourcing and building the scientific, medical and corporate infrastructure around new therapeutic innovations from Japan to address market needs.

RDiscovery sources, evaluates, validates, develops and translates early-stage biotechnology assets from universities and pharmaceutical companies. Investments in first-in-class therapeutics at the pre-clinical stage are supported all the way through to proof of concept and subsequent syndicate financing. RDiscovery generates value by establishing and supporting relationships with pharmaceutical assets to develop biotechnological innovations into established companies, supporting the roles of entrepreneur, venture partner and board governance.

Japan is a fundamental source of pharmaceuticals for patients and accounts for approximately 10% of all new drugs approved by the US FDA. RDiscovery is the foremost venture capital firm that sources Japanese early-stage biotech assets, biasing 60% of its funding to bring Japanese-sourced assets to the global market. Japan has a vast untapped market of highly developed and de-risked innovations. RDiscovery leverages these financial and scientific advantages to bring more innovations to market, faster.